ArticleACS nanoscience Au2025
Evasin and TSLPI Tick Salivary Antigen Subunit Vaccine Nanoparticles Induce Humoral and Cellular Immunity.
Article in ACS nanoscience Au, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evasins: Biology and Therapeutic Potential of Broad-Spectrum Chemokine Inhibitors.Basic & clinical pharmacology & toxicology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tick-borne diseases have increased significantly due to several factors, including climate change. Ticks can carry diverse pathogens, and transmission is facilitated by immunosuppressive tick salivary proteins. Vaccination targeting tick salivary proteins has been proposed as a strategy to enhance broad acquired immunity against tick-borne pathogens. Given the immunosuppressive nature of these proteins, we leveraged the ability of nanoparticles to enhance antigen immunogenicity. We synthesized nanoparticles directly from tick salivary proteins, evasin-3 and tick salivary lectin pathway inhibitor (TSLPI), by desolvation with ethanol and cross-linking. Nanoparticles formulated with the CpG oligonucleotide adjuvant significantly enhanced both humoral and cellular immune responses against both evasin-3 and TSLPI in mice compared to soluble CpG adjuvanted antigens. These results demonstrate the importance of antigen delivery and presentation, particularly for poorly immunogenic antigens, and the potential for protein nanoparticles to be developed as vaccines against diverse tick-borne pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.